Track record · closed signal

Aurinia Pharmaceuticals Inc (AUPH) — closed signal from May 18, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 16, 2026 — +0.1% at the close.

Predicted vs. what happened

AUPH price · publication thesis → realized outcomesplit-adjusted

$14.60 – $15.60Entry zone — fair-value band

$15.45Published — price the day we called it

$17.15Target — the price the thesis aimed for

$19.25Peak — highest point inside the window, not a realized return

$15.47Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 35 days.

At window close

+0.1%

realized, from the publication price to the last close inside the window

Peak gain

+24.6%

peak, from the publication price — not a realized return

S&P 500, same window

+5.4%

SPY over the identical days, dividend-adjusted

Window close

$15.47

last close inside the window, ended August 16, 2026

Peak price

$19.25

peak on June 24, 2026 — not a realized return

Days to target

The thesis — published May 18, 2026

Predicted growth

+11%

over the measurement window

Target price

$17.15

the price the thesis aimed for

Entry zone

$14.60 – $15.60

the fair-value band we waited for

Price at publication

$15.45

published May 18, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Aurinia looks interesting because it is a small healthcare company with plenty of cash, a track record of beating earnings expectations, and insiders buying stock. There is less clear short-term news to push the stock higher, and trading activity is light and tilted negative, so confidence is limited. Still, its valuation and cash give a case for a possible rebound over the next 0-3 months.

Primary drivers

Healthy cash position lowers the chance of forced financing
Lower valuation gives a cushion if shares fall further
Consistent earnings beats build trust in execution
Exposure across healthcare lessens single-factor risk

How it played out

AUPH: target reached in 35 days

Lyra published AUPH at $15.45 with an expected gain of 11% and a $17.15 target. The thesis pointed to its cash position, lower valuation, history of earnings beats, and exposure across healthcare. It also noted limited short-term news and light, negative-leaning trading activity.

The shares reached the target in 35 days. They peaked at $19.25 on June 24, a gain of 24.6% from publication. By the end of the window, the price had fallen back to $15.47. The thesis played out within the stated period, although nearly all of the rise had faded by the close.

What happened during the window

On July 6, Aurinia announced the start of a Phase 4 study of LUPKYNIS combination treatments. On August 6, the company reported quarterly revenue of $83.2 million and net income of $37.4 million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All AUPH signals